Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

Copper-based nanoplatform shows promise against metastatic tumor growth

What happens if cancer cells lose both their mitochondrial energy supply and their glycolytic backup system? This question is central to a new study published in Research by researchers from Northwestern Polytechnical University and collaborating institutions.

10 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

New monoclonal antibody shows promise for preventing Lyme disease

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.

8 Apr 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

Study reveals coffee triggers distinct cytokine responses compared with pure caffeine

A randomized crossover pilot study in healthy adults found that coffee and isolated caffeine produce distinct short-term immune responses despite equivalent caffeine doses. The results suggest non-caffeine coffee compounds may influence cytokine activity and caffeine metabolism, although findings remain preliminary due to the small sample size.

19 Feb 2026

New guidance for the diagnosis and management of inherited hyperbilirubinemia

Inherited hyperbilirubinemia, encompassing Gilbert syndrome, Crigler-Najjar syndrome, Dubin-Johnson syndrome, and Rotor syndrome, represents a spectrum of disorders rooted in genetic defects affecting bilirubin metabolism and transport.

10 Feb 2026

Distinct tau chemical signatures redefine diagnosis across neurodegenerative diseases

Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current "one-size-fits-all" approach to diagnosing and treating these tauopathies.

31 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The Journal of Cystic Fibrsosis.

9 Dec 2025

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

UCI Health launches clinical trial to test investigational cell therapy for lupus

UCI Health has opened a clinical trial to test an investigational cell therapy for lupus with the potential to give patients long-term remission of symptoms.

17 Nov 2025

Understanding how biological sex and gender inequities contribute to suboptimal sepsis treatment

Sepsis continues to be a leading cause of mortality in ICUs worldwide. Despite advances in early detection and treatment, standardized antibiotic dosing frequently ignores patient-level variability-especially that associated with sex-related physiology and gender-influenced care disparities.

31 Oct 2025

Pharmacokinetics News and Research

Further Reading

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Copper-based nanoplatform shows promise against metastatic tumor growth

NIH awards $3.9 million grant to develop a non-opioid pain treatment

CBD shows promise, but this review warns the hype is outpacing the science

Nanomedicine offers targeted solutions for breast cancer treatment

New monoclonal antibody shows promise for preventing Lyme disease

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

Study reveals coffee triggers distinct cytokine responses compared with pure caffeine

New guidance for the diagnosis and management of inherited hyperbilirubinemia

Distinct tau chemical signatures redefine diagnosis across neurodegenerative diseases

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

UCI Health launches clinical trial to test investigational cell therapy for lupus

Understanding how biological sex and gender inequities contribute to suboptimal sepsis treatment

AI indelibly transforms solid tumor drug development

Multimodal nanocarriers offer targeted solutions for tumor treatment

New drug candidates show promise for restoring myelin in MS

Khat use linked to autoimmune hepatitis in young men

Industry Focus - Biopharma eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News